Samcyprone, a proprietary topical formulation of the small molecule diphenylcyclopropenone
(DCPC), is a topical immunomodulator that works by initiating a T-cell response.
A large variety of therapeutic modalities have been suggested for the treatment of AA, which include topical steroids, contact sensitizers such as dinitrochlorobenzene, squaric acid dibutylester and diphenylcyclopropenone
or a tacrolimus, anthralin, nitrogen mustard or minoxidil.
Contact immunotherapy with diphenylcyclopropenone
(DPCP) or squaric acid dibutylester (SADBE) is also recommended for severe AA.
The product is an immunomodulating topical gel containing the active agent, diphenylcyclopropenone
, developed by Hapten.
A team led by Professor Neil Walsh, Director of the Extremes Research Group in the School of Sport, Health & Exercise Sciences at Bangor University administered a chemical called diphenylcyclopropenone
(DPCP) through a patch on the lower back, 20 minutes after exercise bouts of various lengths and intensities.
Later, potent contact allergens namely dinitrochlorobenzene (DNCB) and diphenylcyclopropenone (DPCP) replaced the allergens that were used earlier (33).
The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata.
Topical immunotherapy (squaric acid dibutylester [SADBE] and diphenylcyclopropenone [DPCP]) induces the most significant short-term hair regrowth in children with severe AA (strength of recommendation [SOR]: C, 4 small individual cohort studies and 1 moderately sized retrospective case review).
Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata.
Topical sensitizers, such as squaric acid dibutylester (SADBE) or diphenylcyclopropenone
(DPCP), can be rubbed on the scalp, creating an allergic response and resulting in hair growth, Dr.
Samcyprone, which a proprietary immunomodulating topical gel containing the active agent diphenylcyclopropenone
(DPCP), is currently in Phase 2a clinical trials for the treatment of alopecia areata, warts and cutaneous metastases of malignant melanoma.
(DPCP) is a contact immunotherapy that has some proven benefit with extensive alopecia areata (LOE=2b).